Reframing immune-mediated inflammatory diseases
Boutrid N, Rahmoune H, Schett G, McInnes I, Neurath M (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 385
Article Number: e75
Journal Issue: 21
DOI: 10.1056/NEJMc2114894
Abstract
We were surprised to find that celiac disease was not among the panel of disorders discussed by Schett et al. (Aug. 12 issue)1 in their review article on cytokines and immune-mediated inflammatory conditions. It is well established that cytokine release is at the core of the structural damage and subsequent clinical manifestations in celiac disease, and we note in particular the evolving role of interleukins (mainly interleukin-15).2
In fact, interleukin-15 has a crucial role in innate and adaptive immune responses and is overexpressed in various autoimmune conditions, including celiac disease.3 This interleukin-15 action is orchestrated by tumor necrosis factor α and implicates the innate lymphoid cells; these two components are involved in the celiac-immunomediated enteropathy and several extraintestinal manifestations of celiac disease.4 It is not surprising that numerous trials — including trials in animal models and clinical trials, notably the PRV-015 in Gluten-free Diet Non-responsive Celiac Disease (PROACTIVE) trial5 — are exploring the option of blocking interleukin-15 to decrease or resolve lesions caused by celiac disease.5
Authors with CRIS profile
Involved external institutions
Algeria (DZ)How to cite
APA:
Boutrid, N., Rahmoune, H., Schett, G., McInnes, I., & Neurath, M. (2021). Reframing immune-mediated inflammatory diseases. New England Journal of Medicine, 385(21). https://doi.org/10.1056/NEJMc2114894
MLA:
Boutrid, Nada, et al. "Reframing immune-mediated inflammatory diseases." New England Journal of Medicine 385.21 (2021).
BibTeX: Download